Pfizer

JULY 8, 2022

Today’s approval is based on data from a Phase 3 clinical trial of 2,260 participants 12 through 15 years of age. A two-dose primary series of the vaccine (30-µg dose) elicited SARS-CoV-2–neutralizing antibody geometric mean titers (GMTs) of 1,239.5, GMTs) in an earlier analysis. IMPORTANT SAFETY INFORMATION . have a fever.

FDA Approval 102

FDA Approval Vaccine Vaccination Clinical Trials 102

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Pfizer

JULY 26, 2022

Tell your vaccination provider about all of the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. The Pfizer-BioNTech COVID-19 Vaccine authorized for use in children 6 months through 11 years of age should not be used interchangeably with COMIRNATY® (COVID-19 Vaccine, mRNA). has a fever.

Vaccine 111

Vaccine Vaccination Protein Immune Response 111

Pfizer

SEPTEMBER 28, 2022

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5),

Vaccine 101

Vaccine Vaccination Medicine Clinical Trials 101

Pfizer

JULY 19, 2022

Tell your vaccination provider about all of the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. IMPORTANT SAFETY INFORMATION. has had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart). has a fever. has received another COVID-19 vaccine.

Vaccine 100

Vaccine Vaccination Medicine Clinical Trials 100

XTalks

DECEMBER 24, 2020

Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals.

Life Science 111

Life Science Vaccine Vaccination Gene 111

Pfizer

JULY 8, 2022

IMPORTANT SAFETY INFORMATION Tell your vaccination provider about all the vaccine recipient’s medical conditions, including if the vaccine recipient: has any allergies. has had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart). has a fever. has received another COVID-19 vaccine.

Vaccine 81

Vaccine Vaccination Clinical Trials Clinical Trials 81

Pfizer

SEPTEMBER 16, 2022

Today’s recommendation is based on Phase 2/3 clinical data from participants 5 through 11 years of age who received a 10-µg booster dose of COMIRNATY approximately 6 months after completing the two-dose primary series. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies.

Marketing 75

Marketing Vaccine Vaccination Clinical Trials 75

Pfizer

OCTOBER 19, 2022

Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 5), COMIRNATY® (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine. have a fever. have a bleeding disorder or are on a blood thinner.

Vaccine 40

Vaccine Vaccination Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 23, 2020

. Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. The Company is marketing these products globally, in over 150 countries.

Vaccine 52

Vaccine Vaccination Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. Under the signed license agreement, Aurobindo Pharma has obtained the exclusive rights to commercialize in India and to UNICEF and non-exclusive rights in other select emerging and developing markets.

Vaccine 52

Vaccine Vaccination Manufacturing Antibody 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. In older adults, the same vaccine elicited neutralizing antibodies 1.6

Vaccine 92

Vaccine Vaccination Antibody Life Science 92